Back to search

Article

Targeting a proteolytic neo-epitope of CUB-domain containing protein 1 in RAS-driven cancer

2021-06-15

Abstract excerpt

A central challenge for any therapeutic is targeting diseased over normal cells. Proteolysis is frequently upregulated in disease and can generate proteoforms with unique neo-epitopes. We hypothesize that targeting proteolytic neo-epitopes can enable more effective and safer treatments, reflecting a conditional layer of disease-specific regulation. Here, we characterized the precise proteolytic isoforms of CUB dom...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0e030fec-86ed-5895-b88c-d8ae98ea86a3
DOI
10.1101/2021.06.14.448427
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Targeting a proteolytic neo-epitope of CUB-domain containing protein 1 in RAS-driven cancerDOI 10.1101/2021.06.14.448427
A general approach for selection of epitope-directed binders to proteinsSemantic proximity
A general approach for selection of epitope-directed binders to proteinsSemantic proximity
Targeting the Interplay of Proteins through PROTACs for the Management of Cancer and Associated DisordersSemantic proximity
The cell surface glycoprotein CDCP1 in cancer—Insights, opportunities, and challengesSemantic proximity
PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat CancerSemantic proximity
New-generation advanced PROTACs as potential therapeutic agents in cancer therapySemantic proximity
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?Semantic proximity
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapySemantic proximity
bioPROTACs as versatile modulators of intracellular therapeutic targets: Application to proliferating cell nuclear antigen (PCNA)Semantic proximity
Welding PROxAb Shuttles: A modular approach for generating bispecific antibodies via site-specific protein-protein conjugationSemantic proximity
Clinical considerations for the design of PROTACs in cancerSemantic proximity
Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteinsSemantic proximity
Select a neighboring publication to make it the new centre.